Inventor · disambiguated record
Xiaozhu Wang
Also filed as: WANG XIAOZHU
9 granted patents·10 pending applications·9 citations·filing 2012–2025
80Inventor score
Files withIMPACT THERAPEUTICS SHANGHAI INC14IMPACT THERAPEUTICS INC4SHENZHEN YINUOZHIYU TECH CO LTD1
Top patents by PatentIndex Score
19 records- 0177US9926304B21-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereofIMPACT THERAPEUTICS INC·Filed 2016·Granted Mar 27, 2018·3 cites·4 claims
- 0277US9102631B21-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereofIMPACT THERAPEUTICS INC·Filed 2012·Granted Aug 11, 2015·3 cites·3 claims
- 0375US11345710B2Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2018·Granted May 31, 2022·1 cites·20 claims
- 0467US2025320219A1Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2025·Application pending·0 cites
- 0563US11358955B21-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereofIMPACT THERAPEUTICS INC·Filed 2019·Granted Jun 14, 2022·0 cites·22 claims
- 0660US2025215013A1Substituted tricyclic compounds as parp inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2023·Application pending·0 cites
- 0759US12479848B2Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Granted Nov 25, 2025·0 cites·19 claims
- 0859US2024368169A1Substituted tricyclic compounds as parp inhibitors and use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 0958US2024409538A1Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1057US2024208969A1Substituted fused bicyclic compounds as parp inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1156USD1091881SNight lightSHENZHEN YINUOZHIYU TECH CO LTD·Filed 2024·Granted Sep 2, 2025·2 cites·1 claims
- 1256US2024059695A1SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOFIMPACT THERAPEUTICS SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1356US2024124464A1Substituted fused bicyclic compound as kinase inhibitor and use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1454US12492197B23,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Granted Dec 9, 2025·0 cites·20 claims
- 1554US10316027B21-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereofIMPACT THERAPEUTICS INC·Filed 2018·Granted Jun 11, 2019·0 cites·3 claims
- 1651US2022354859A1Substituted imidazoquinoxaline compounds and uses thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1751US2022259211A1Substituted pyrazoloquinazolinone compounds and application thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1851US2024010655A1Dihydroimidazo pyrimido pyrimidinone compoundIMPACT THERAPEUTICS SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1946US11547703B2Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereofIMPACT THERAPEUTICS SHANGHAI INC·Filed 2018·Granted Jan 10, 2023·0 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →